• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Internet Journal of Academic Physician Assistants >Is bevacizumab plus chemotherapy superior to chemotherapy alone in treatment of metastasic colorectal cancer?
【24h】

Is bevacizumab plus chemotherapy superior to chemotherapy alone in treatment of metastasic colorectal cancer?

机译：贝伐单抗联合化疗在转移性结直肠癌治疗中是否优于单纯化疗？

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Colorectal cancer is the third most commonly diagnosed cancer and second leading causes of cancer deaths in the United States. Over the past 12 years, significant progress has been made in the systemic treatment of this malignant condition. The development of targeted biological therapies, such as anti-angiogenesis therapy with bevacizumab, has significantly impacted the survival of patients with cancer. Yet, despite these advances, nearly all patients with metastatic colorectal cancer will succumb to the disease. This review summarizes the results from certain phase-III clinical studies to determine if bevacizumab combined with chemotherapy is superior to chemotherapy alone in treatment of metastatic colorectal cancer. Studies found that the addition of bevacizumab to chemotherapy significantly improves response rates, TTP, PFS and overall survival for first-line mCRC. The reported severe adverse effects were similar to that reported in phase II clinical trials. Bevacizumab plus chemotherapy is superior to chemotherapy alone in treatment of metastatic colorectal cancer and was proven in the phase III randomized controlled clinical studies.
机译：大肠癌是美国第三大最常被诊断的癌症，也是癌症死亡的第二大主要原因。在过去的12年中，在系统治疗这种恶性疾病方面取得了重大进展。靶向生物疗法的发展，例如使用贝伐单抗的抗血管生成疗法，已显着影响癌症患者的生存。然而，尽管取得了这些进展，但几乎所有转移性结直肠癌患者都会屈服于该疾病。这篇综述总结了某些III期临床研究的结果，以确定贝伐单抗联合化疗是否优于单纯化疗治疗转移性结直肠癌。研究发现，在化疗中加入贝伐单抗可显着提高一线mCRC的缓解率，TTP，PFS和总体生存率。报告的严重不良反应与II期临床试验中报告的相似。贝伐单抗联合化疗在转移性结直肠癌的治疗中优于单纯化疗，并已在III期随机对照临床研究中得到证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号